{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457285800
| IUPAC_name = (4''R'')-4-[(2''S'')-2-({2-[(1''S'')-1-amino-2-methylbutyl]- 4,5-dihydro-1,3-thiazol-5-yl}formamido)-4-methylpentanamido]-4-<nowiki/>{[(1''S'')- 1-<nowiki/>{[(3''S'',6''R'',9''S'',12''R'',15''S'',18''R'',21''S'')- 18-(3-aminopropyl)-12-benzyl-15-(butan-2-yl)-3-(carbamoylmethyl)- 6-(carboxymethyl)-9-(1''H''-imidazol-5-ylmethyl)-2,5,8,11,14,17,20- heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}- 2-methylbutyl]carbamoyl}butanoic acid
| image = Bacitracin A.svg
| image2 = Bacitracin ball-and-stick.png
<!--Clinical data-->
| tradename = Baciim
| Drugs.com = {{drugs.com|monograph|bacitracin}}
| pregnancy_AU = D
| pregnancy_US = C
| legal_AU = S4
| legal_US = OTC for topical administration; Rx-only for injection
| routes_of_administration = [[外用藥物|外用藥物]]、[[肌肉注射|肌肉注射]]
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1405-87-4
| ATC_prefix = D06
| ATC_suffix = AX05
| ATC_supplemental =  {{ATC|J01|XX10}} {{ATC|R02|AB04}} {{ATCvet|A07|AA93}}
| PubChem = 439542
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00626
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10481985
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 58H6RWO52I
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00128
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200558
<!--Chemical data-->
| C=66 | H=103
| N=17 | O=16
| S=1
| molecular_weight = 1422.69 g/mol
| smiles = O=C(O)C[C@H]3NC(=O)[C@H](Cc1cncn1)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC3=O)NC(=O)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C4N=C(SC4)\nC(N)C(C)CC)C(C)CC)C(C)CC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36?,37?,40-,41+,42+,43-,44+,45-,46-,47+,48?,52?,53-,54-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CLKOFPXJLQSYAH-NVOBBBONSA-N
}}

'''桿菌肽'''（bacitracin）是由[[枯草桿菌|枯草桿菌]]的變種「崔西」之地衣狀菌素[[生物|有機體]]所產生的相關[[环肽|环肽]]之混合物，在1945年首次分離出來。這些肽藉由干擾"肽聚醣合成"及[[細胞壁|細胞壁]]而破壞[[革蘭氏陽性菌|革蘭氏陽性菌]]及[[革兰氏阴性菌|革兰氏阴性菌]]的微生物體。

桿菌肽，主要是用來作為外用製劑（因為內服使用時，它會引起腎損害）。

雖然使用任何抗生素會形成[[抗生素抗藥性|抗生素抗藥性]]，而杆菌肽局部的外用較少會產生如內服使用的腎損害。然而，如桿菌肽一般的抗生素機制已顯示出會有皮膚刺激的副作用，並且可能減慢癒合的程度。<ref>{{cite journal|pmid=15280871|year=2004|last1=Spann|first1=CT|last2=Taylor|first2=SC|last3=Weinberg|first3=JM|title=Topical antimicrobial agents in dermatology|volume=50|issue=7|pages=407–21|doi=10.1016/j.disamonth.2004.05.011|journal=Disease-a-month : DM}}</ref><ref>{{cite journal|pmid=21247665|year=2011|last1=Trookman|first1=NS|last2=Rizer|first2=RL|last3=Weber|first3=T|title=Treatment of minor wounds from dermatologic procedures: A comparison of three topical wound care ointments using a laser wound model|volume=64|issue=3 Suppl|pages=S8–15|doi=10.1016/j.jaad.2010.11.011|journal=Journal of the American Academy of Dermatology}}</ref>

==醫療用途==
[[Image:Bacitracin_ointment.jpg|thumb]] 
杆菌肽是用于人类医学的多肽抗生素，并被“[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）批准用于鸡和火鸡”，尽管在动物使用会导致[[抗生素耐药性|抗生素耐药性]]。<ref name="disc">[http://discovermagazine.com/2007/sep/better-planet Antibiotic use on the farm hurts people—and doesn’t help the bottom line.] {{Wayback|url=http://discovermagazine.com/2007/sep/better-planet |date=20070925063617 }} [[Discover_Magazine|Discover Magazine]].  Accessed on September 16, 2007.</ref>

<!--As bacitracin zinc salt, in combination with other topical antibiotics (usually [[polymyxin_B|polymyxin B]] and [[neomycin|neomycin]]) as an [[ointment|ointment]] ("triple antibiotic ointment," with a common brand name [[Neosporin|Neosporin]]), it is used for topical treatment of a variety of localized skin and eye infections, as well as for the prevention of wound [[infection|infection]]s. A non-ointment form of ophthalmic solution is also available for eye infections.<ref>{{cite web|url=http://www.healthgrades.com/drug-ratings/drug/information/1246/Triple%20Antibiotic|title=Healthgrades > Find a Doctor > Doctor Reviews > Hospital Ratings|publisher=|access-date=2016-08-13|archive-url=https://web.archive.org/web/20110523141000/http://www.healthgrades.com/drug-ratings/drug/information/1246/Triple%20Antibiotic|archive-date=2011-05-23|dead-url=yes}}</ref>

Although allergic cross reaction with sulfa drugs has been occasionally reported, bacitracin-containing topical preparations remain a possible alternative to [[silver_sulfadiazine|silver sulfadiazine]] (Silvadene) for burn patients with a sulfa allergy. 
[[image:3D_Aminated_Chem_Struct_Bacitracin_A.gif|thumb]]
<br />
Bacitracin can also be bought in pure form for those with allergies to the polymyxin B and neomycin components of the combination product.

Bacitracin is also commonly used as an aftercare antibiotic on tattoos and circumcision.  It is preferred over combination products such as Neosporin because of its fewer ingredients, which lowers chances of an allergic reaction.<ref>{{cite web|url=http://tattoo.about.com/cs/tatfaq/a/aftrcr_cntrdctn.htm|title=The Right Way to Take Care of a New Tattoo|publisher=}}</ref>

[[File:Epikutanni-test.jpg|thumb]]]]
In 2005–06, it was the sixth-most-prevalent [[allergen|allergen]] in [[patch_test|patch test]]s (9.2%).<ref>Zug KA, Warshaw EM, Fowler JF Jr, Maibach HI, Belsito DL, Pratt MD, Sasseville D, Storrs FJ, Taylor JS, Mathias CG, Deleo VA, Rietschel RL, Marks J. Patch-test results of the North American Contact Dermatitis Group 2005–2006. Dermatitis. 2009 May–Jun;20(3):149-60.</ref>

It was voted [[Allergen_of_the_Year|Allergen of the Year]] in 2003 by the American Contact Dermatitis Society.<ref>[http://www.contactderm.org/i4a/pages/index.cfm?pageid=3467 History of Allergen of the Year.] [[American_Contact_Dermatitis_Society|American Contact Dermatitis Society]]. Accessed on April 24, 2014.</ref>

In infants, bacitracin is rarely administered [[intramuscular|intramuscular]]ly for the treatment of [[staphylococcal|staphylococcal]] [[pneumonia|pneumonia]] and [[empyema|empyema]] when due to organisms shown susceptible to bacitracin. This use is extremely limited, since bacitracin is [[nephrotoxic|nephrotoxic]] and the concentration of bacitracin in the blood must be followed closely.<ref>{{Cite web |url=http://www.sagentpharma.com/Products/Bacitracin/Catalog/Bacitracin_PI.pdf |title=FDA-approved IM injection package insert for bacitracin. |access-date=2016-08-13 |archive-url=https://web.archive.org/web/20110516001228/http://www.sagentpharma.com/Products/Bacitracin/Catalog/Bacitracin_PI.pdf |archive-date=2011-05-16 |dead-url=yes }}</ref>

Bacitracin can be used to distinguish ''[[Streptococcus_pyogenes|Streptococcus pyogenes]]'' from other "strep" bacteria,<ref name="urlStreptococci">{{cite web |url=http://emedicine.medscape.com/article/228936-diagnosis |title=Streptococcus Group A Infections: Differential Diagnoses & Workup |work= |accessdate=Sep 23, 2009}}</ref> with ''[[S._pyogenes|S. pyogenes]]'' being sensitive to bacitracin and others resistant. In this case bacitracin is used to distinguish ''[[S._pyogenes|S. pyogenes]]'' from other ''[[streptococcus|β-hemolytic streptococci]]''.

It is also commonly used to distinguish ''[[Haemophilus_influenzae|Haemophilus influenzae]]'' colonies amongst respiratory flora, since ''[[Haemophilus_influenzae|H. influenzae]]'' is intrinsically resistant to bacitracin, colonies form within the [[Agar_diffusion_test|zone of inhibition]].
-->
===活動及藥敏數據的頻譜 ===
<!--Bacitracin is a broad spectrum antibiotic. It targets both Gram-positive and Gram-negative bacteria, especially those that cause skin infections. The following represents susceptibility data for a few medically significant microorganisms.
* ''[[Staphylococcus_aureus|Staphylococcus aureus]]'' – ≤0.03 μg/mL – 700 μg/mL
* ''[[Staphylococcus_epidermidis|Staphylococcus epidermidis]]'' – 0.25 μg/mL – >16 μg/mL
* ''[[Streptococcus_pyogenes|Streptococcus pyogenes]]'' – 0.5 μg/mL – >16 μg/mL
<ref>http://www.toku-e.com/Assets/MIC/Bacitracin.pdf</ref>

== 作用機理 ==
{{main article|Bactoprenol phosphate}}
Bacitracin interferes with the dephosphorylation of [[C55-isoprenyl_pyrophosphate|C<sub>55</sub>-isoprenyl pyrophosphate]], a molecule that carries the building-blocks of the [[peptidoglycan|peptidoglycan]] bacterial [[cell_wall|cell wall]] outside of the inner membrane.<ref>[http://www.pnas.org/cgi/content/abstract/68/12/3223 Mechanism of Action of Bacitracin: Complexation with Metal Ion and C55-Isoprenyl Pyrophosphate] K. John Stone and Jack L. Strominger</ref>

Some have claimed that bacitracin is a [[protein_disulfide_isomerase|protein disulfide isomerase]] inhibitor, but this is disputed by ''in vitro'' studies.<ref>{{Cite journal 
| doi = 10.1111/j.1742-4658.2010.07660.x 
| pmid = 20477872 
| title = Bacitracin is not a specific inhibitor of protein disulfide isomerase 
| year = 2010 
| last1 = Karala | first1 = A. R. 
| last2 = Ruddock | first2 = L. W. 
| journal = FEBS Journal 
| volume = 277 
| issue = 11 
| pages = 2454–2462
}}</ref><ref>{{Cite journal
| issue = 5
| volume = 60
| journal = Kidney International
| pages = 1756–1764
| year = 2001
| doi = 10.1046/j.1523-1755.2001.00991.x
| pmid = 11703593
| title = Bacitracin inhibits fibronectin matrix assembly by mesangial cells in high glucose | url = https://archive.org/details/sim_kidney-international_2001-11_60_5/page/1756
| first4 = R.
| last2 = Wahab | first1 = B. | first2 = N.
| last3 = Roberts
| last4 = Mason | first3 = T.
| last1 = Weston
}}</ref>
-->
==發展歷史==
<!--The drug's unique name derives from the fact that it was isolated by John T. Goorley from a girl named Margaret Treacy (1936–1994):<ref>{{Cite web |url=https://files.nyu.edu/jmm257/public/other/bacitracin.html |title=存档副本 |access-date=2016-08-13 |archive-url=https://web.archive.org/web/20140428190211/https://files.nyu.edu/jmm257/public/other/bacitracin.html |archive-date=2014-04-28 |dead-url=yes }}</ref> The surname was misspelled and the name was shortened to the more common spelling Tracy

<blockquote>''One strain isolated from tissue debrided from a compound fracture of the tibia was particularly active.  We named this growth-antagonistic strain for the patient, "Tracy I."  When cell-free filtrates of broth cultures of this bacillus proved to possess strong antibiotic activity and to be non-toxic, further study seemed warranted.  We have called this active principle "Bacitracin.''"<ref>Johnson B, Anker H, Meleney F (1945). "Bacitracin: a new antibiotic produced by a member of the B. subtilis group".</blockquote>''[[Science_(journal)|Science]]'' '''102''' (2650): 376–377.</ref></blockquote>
It was approved by FDA in 1948.
-->
== 合成性 ==
<!--Bacitracin is synthesised via what is called [[nonribosomal_peptide_synthetase|nonribosomal peptide synthetase]]s (NRPSs), which means that [[ribosome|ribosome]]s are not directly involved in its [[nonribosomal_peptide|synthesis]].

bacABC is involved in synthesis.<ref>{{Cite journal
| last1 = Murphy | first1 = T.
| last2 = Roy | first2 = I.
| last3 = Harrop | first3 = A.
| last4 = Dixon | first4 = K.
| last5 = Keshavarz | first5 = T.
| title = Effect of oligosaccharide elicitors on bacitracin a production and evidence of transcriptional level control
| journal = Journal of biotechnology
| volume = 131
| issue = 4
| pages = 397–403
| year = 2007
| pmid = 17825450 
| doi = 10.1016/j.jbiotec.2007.07.943
}}</ref>

Bacitracin is commercially manufactured by growing the bacteria ''Bacillus subtilis var Tracy I'' in a container of liquid [[growth_medium|growth medium]]. Over time, the bacteria synthesizes the antibiotic and secretes the antibiotic into the medium. The antibiotic is then extracted from the medium using chemical processes.
-->
== 複合物 ==
<!--Bacitracin is composed of a mixture of related compounds with varying degrees of antibacterial activity. Notable fractions include bacitracin A, A1, B, B1, B2, C, D, E, F, G, and X.<ref>"Committee for Veterinary Medicinal Products Bacitracin." Ema.europa.eu. The European Agency for the Evaluation of Medicinal Products, June 1998. Web. 18 Jan. 2013</ref> Bacitracin A has been found to have the most antibacterial activity. Bacitracin B1 and B2 have similar potencies and are approximately 90% as active as bacitracin A.<ref>Bell, Robert G. "Preparative High-Performance Liquid Chromatographic Separation and Isolation of Bacitracin Components and Their Relationship to Microbiological Activity." Journal of Chromatography 590 (1992): 163–68. Web. 21 Aug. 2012.</ref> Other bacitracin components including F and X do not appear to be extensively studied.
-->
== 註釋 ==
{{Reflist|2}}

{{Cell wall disruptive antibiotics}}
{{Antibiotics and chemotherapeutics for dermatological use}}
{{Throat preparations}}

[[Category:多肽类抗生素|Category:多肽类抗生素]]
[[Category:環肽|Category:環肽]]